Martin V.
- Country
- Germany
- Department
- Klinik und Poliklinik für Innere Medizin III
Research Overview
- INDIE: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
- Evaluation of BrECADD Versus Escalated BEACOPP in First-Line Treatment of Advanced Hodgkin Lymphoma: A Randomized Controlled Trial
- Phase II Trial of Pembrolizumab Followed by Consolidation Radiotherapy in Patients with Early-Stage Favorable Classic Hodgkin Lymphoma
Data & Insights
Has run more than one trial at 42 of 166 partner sites.
Specializations
Lymphoma Research
This investigator specializes in developing innovative treatments for classical Hodgkin lymphoma, with particular emphasis on early-stage and advanced manifestations of the disease.
- Early-Stage Unfavorable Classical Hodgkin Lymphoma
- Advanced Stage Hodgkin Lymphoma
- PET-guided Treatment Strategies
The investigator focuses on therapeutic applications in immunotherapy approaches and individualized treatment protocols.
Treatment Innovation
The research portfolio encompasses the evaluation of novel therapeutic regimens, including checkpoint inhibition and comparative assessment of treatment protocols.
- Immunotherapy Integration
- Treatment-Related Morbidity Assessment
- Progression-Free Survival Studies
Key interests include therapeutic efficacy optimization and toxicity reduction strategies.
Clinical Methodology
The investigator implements prospective multicenter trials focusing on therapeutic interventions in lymphoma treatment.
- PET-Positive Residual Lesion Management
- Age-Specific Treatment Protocols
- Radiotherapy Integration
Research encompasses treatment response assessment and therapeutic protocol optimization.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.